发布求助
文献互助 智能选刊 最新文献

The Women's Oncology Review最新文献

筛选
英文 中文
Vascular endothelial growth factor (VEGF) inhibitors in cancer therapy: An update 血管内皮生长因子(VEGF)抑制剂在癌症治疗中的最新进展
The Women's Oncology Review Pub Date : 2006-09-01 DOI: 10.1080/14733400600739731
J. Homsi, Lori C. Kim, P. Munster, C. Chodkiewicz, A. Daud
{"title":"Vascular endothelial growth factor (VEGF) inhibitors in cancer therapy: An update","authors":"J. Homsi, Lori C. Kim, P. Munster, C. Chodkiewicz, A. Daud","doi":"10.1080/14733400600739731","DOIUrl":"https://doi.org/10.1080/14733400600739731","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129175516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation after breast conservative surgery or after mastectomy reduces local recurrence and improves overall survival in breast cancer 乳房保守手术或乳房切除术后的放疗减少了乳腺癌的局部复发，提高了总体生存率
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.1080/14733400600733387
T. Buchholz
{"title":"Radiation after breast conservative surgery or after mastectomy reduces local recurrence and improves overall survival in breast cancer","authors":"T. Buchholz","doi":"10.1080/14733400600733387","DOIUrl":"https://doi.org/10.1080/14733400600733387","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123261221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer B7-H4是一种新的膜结合蛋白，是卵巢癌的候选血清和组织生物标志物
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.3109/14733400600857822
Alessandra Rossi
{"title":"B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer","authors":"Alessandra Rossi","doi":"10.3109/14733400600857822","DOIUrl":"https://doi.org/10.3109/14733400600857822","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128373822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
High dose ifosfamide plus doxorubicin for advanced or metastatic gynecologic sarcomas 高剂量异环磷酰胺加阿霉素治疗晚期或转移性妇科肉瘤
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.3109/14733400600799800
M. Hensley
{"title":"High dose ifosfamide plus doxorubicin for advanced or metastatic gynecologic sarcomas","authors":"M. Hensley","doi":"10.3109/14733400600799800","DOIUrl":"https://doi.org/10.3109/14733400600799800","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128283019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer 多西紫杉醇作为转移性乳腺癌的二线治疗比紫杉醇更有效
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.3109/14733400600615717
Aileen L. Chen, A. Pavlick
{"title":"Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer","authors":"Aileen L. Chen, A. Pavlick","doi":"10.3109/14733400600615717","DOIUrl":"https://doi.org/10.3109/14733400600615717","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"06 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127242912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Current controversies in the biology and management of ovarian tumors of low malignant potential 低恶性潜能卵巢肿瘤的生物学和治疗的当前争论
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.3109/14733400600604448
W. Winter, Douglas N. Brown, C. Leath
{"title":"Current controversies in the biology and management of ovarian tumors of low malignant potential","authors":"W. Winter, Douglas N. Brown, C. Leath","doi":"10.3109/14733400600604448","DOIUrl":"https://doi.org/10.3109/14733400600604448","url":null,"abstract":"AbstractGenerally considered indolent, ovarian tumors of low malignant potential (LMP) have a small but finite risk of aggressive behavior. There is controversy surrounding the management of both the indolent and aggressive variants of ovarian LMP tumors. This review will explore the recent advances in the understanding of the genetic composition, pathologic differences and controversies in clinical management of this unique group of ovarian tumors.","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132179794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of the Axilla 腋窝管理
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.1007/978-3-319-46356-8_15
J. Benson, V. Pitsinis
{"title":"Management of the Axilla","authors":"J. Benson, V. Pitsinis","doi":"10.1007/978-3-319-46356-8_15","DOIUrl":"https://doi.org/10.1007/978-3-319-46356-8_15","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126346323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance 卵巢黏液性肿瘤的表达谱鉴定具有临床病理意义的基因
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.1080/14733400600674227
M. Cassone
{"title":"Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance","authors":"M. Cassone","doi":"10.1080/14733400600674227","DOIUrl":"https://doi.org/10.1080/14733400600674227","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"100 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134481810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Biochemical recurrent ovarian cancer: CA 125 elevation without symptoms or clinical evidence of disease. What is the optimal management? 生化复发性卵巢癌:ca125升高，无症状或疾病的临床证据。什么是最优管理?
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.1080/14733400601143453
E. Berry, J. Hurteau
{"title":"Biochemical recurrent ovarian cancer: CA 125 elevation without symptoms or clinical evidence of disease. What is the optimal management?","authors":"E. Berry, J. Hurteau","doi":"10.1080/14733400601143453","DOIUrl":"https://doi.org/10.1080/14733400601143453","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"253 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115200668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Is the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer? HERA试验是我们正在寻找的英雄:在her2阳性乳腺癌的辅助化疗后曲妥珠单抗?
The Women's Oncology Review Pub Date : 2006-03-01 DOI: 10.1080/14733400600738659
J. M. Kaplan, G. Marx
{"title":"Is the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer?","authors":"J. M. Kaplan, G. Marx","doi":"10.1080/14733400600738659","DOIUrl":"https://doi.org/10.1080/14733400600738659","url":null,"abstract":"","PeriodicalId":217834,"journal":{"name":"The Women's Oncology Review","volume":"241 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122456528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书